openPR Logo
Press release

Plans for Rocklatan to launch in Europe

06-25-2019 04:39 PM CET | Health & Medicine

Press release from: SMi Group

Ophthalmic Drugs 2019

Ophthalmic Drugs 2019

SMi Group reports: After the launch of Rocklatan in the USA, Aerie Pharmaceuticals will be discussing plans for a European approval at the Ophthalmic Drugs conference this November

Last month Aerie Pharmaceuticals announced that they had received approval from the FDA for Rocklatan, the once a day eye drop designed specifically for patients with open-angle glaucoma, reducing IOP elevation*, making them the first company to get to market with this innovative product. The drug has been released in the US with plans being made for a European approval.

At SMi’s 3rd annual Ophthalmic Drugs conference, taking place in London on 18th -20th November 2019, Mitchell de Long, Vice President of Chemistry from Aerie Pharmaceuticals will discuss the launch of Rocklatan in the USA, with a focus on drug development and more specifically the ROCK inhibitor class of drugs. He will share his experiences on gaining the first FDA approval for a PG combination product and discuss the future landscape for Glaucoma treatment.

Following Mitchell’s presentation on Tuesday 19th November, Naj Sharif, Vice President of Global Ophthalmology at Santen Inc USA, will continue in a similar vein where he will focus on novel treatment modalities for managing ocular hypertension and Glaucoma.

Mitchell and Naj will also be chairing the Conference on both Day One and Day Two.

The brochure with the full programme and speaker line-up is available online at www.ophthalmicdrugs.com

For those interested in attending, there is a £300 early bird discount on booking expiring on 28th June. Places can be reserved at www.ophthalmicdrugs.com

*Glaucoma.org/news

Ophthalmic Drugs
Conference: 19th-20th November 2019
Focus Day: 18th November 2019
Copthorne Tara Hotel, London, UK
#OphthalmicDrugs
Ophthalmic Drugs 2019 is proudly sponsored by Experimentica and ProMed Pharma.

For exclusive tailored sponsorship/table-top opportunities contact: Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 / Email: nhoward@smi-online.co.uk

---end---

SMi Group Ltd
Registered & Head Office: SMi Group Ltd, India House, 45 Curlew Street, London, SE1 2ND
Contact Neill Howard on nhoward@smi-online.co.uk

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Plans for Rocklatan to launch in Europe here

News-ID: 1787724 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for Ophthalmic

Ophthalmic Trial Frames Market Depth Survey Report 2019| Topcon, Luneau, Takagi …
Ophthalmic trial frames are adjustable frames that are used to hold lenses during refraction test and during retinoscopy test of the eye. Ophthalmic trial frames are eyeglasses designed in such a way that different lenses can be inserted and can be used to correct refractive errors of vision. Ophthalmic trial frames are light weight, adjustable and should have a comfortable nose resting and can be adjusted to allow accurate centering.
Ophthalmic Eye Shield Market Segmentation By Material type Aluminium Ophthalmic …
Eye shields are advised for use in the eye while a periorbital surgery to avoid any injury to the globe. Ophthalmic eye shields are used for postoperative ocular protection. Ophthalmic eye shields protect the cornea and retina while any eye surgery or laser treatment. Ophthalmic eye shields are highly preferred for cataract surgeries in the elder population and blepharitis correction especially for children. According to WHO, The World Health Organization,
04-08-2019 | Health & Medicine
Fact.MR
Eye socket Implants Market Offered in New Research Forecasted through 2026 // Ke …
The global Eye socket Implants market is expected to see remarkable growth in the forecast period due to increase in work-related eye injuries. Increase in the number of patients drives the overall eye socket implants market. Higher adoption of surgeries in higher economic regions propels the Eye socket Implants Market. Others factors like increasing prevalence and incidence of eye-related disease, changing lifestyle pattern are the factors which are fueling the
Ophthalmic Surgical Technologies Market - Femtosecond Systems Likely to Dominate …
The global ophthalmic surgical technologies market is driven mainly by the growing funding in the healthcare sector and the rising awareness about eye care, added to the rising prevalence of eye diseases. The ophthalmic surgical technologies market has enjoyed a supportive regulatory and economic structure in most regions in the recent past and is thus likely to continue on the strong growth trajectory it has exhibited in recent years. Increasing
Ophthalmic Lasers Market: Demand for Ophthalmic Lasers to Remain Higher in North …
Lasers have become an essential part of treatment modality for a number of practicing ophthalmologist. Ophthalmic lasers have gained prominence with the popularity of laser-assisted surgeries for rectifying nearsightedness or myopia. The increasing incidence of ophthalmic disorders and rise in geriatric population in various regions have boosted the application of different types of lasers in treating specific eye problems and improving vision. Technological advances have significantly increased the safety and
Ophthalmic Ultrasound Device Market: A-scan Ophthalmic Ultrasound Devices High i …
Global Ophthalmic Ultrasound Device Market: Snapshot The constantly increasing percentage of the geriatric population across the world is widely considered as the primary factor augmenting the demand for ophthalmic ultrasound devices. The high geriatric population is directly linked to the increasing patient count for ocular diseases and disorders, along with chronic diseases such as diabetes. The increasing levels of pollution are also responsible for the high volume of ovular disorders across